Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of two systematic review(s)/meta-analysis(es). ^[1-2]
• Deutetrabenazine and valbenazine both demonstrated significant improvements in reducing tardive dyskinesia (TD) symptoms, with clinical trials showing significant reductions in Abnormal Involuntary Movement Scale (AIMS) scores compared to placebo.
• Vesicular Monoamine Transporter-2 (VMAT-2) inhibitors, including deutetrabenazine, were more effective than placebo for achieving a 'slight improvement' in psychotic symptoms (RR (relative risk) 1.77, 95% CI (confidence interval) 1.03–3.04) but not for 'moderate improvement' (RR 2.81, 95% CI 0.27–29.17).
• There were no significant differences in the effectiveness of deutetrabenazine compared to valbenazine in managing TD symptoms, with both showing similar efficacy across different population types, including the Asian population.
• Deutetrabenazine and valbenazine both demonstrated favorable safety profiles, with low rates of serious adverse events, including no significant increase in QT interval prolongation, parkinsonism, suicidal ideation, or mortality compared to placebo.
• VMAT-2 inhibitors, including deutetrabenazine, showed a reduced risk of tardive dyskinesia compared to dopamine antagonists, with no significant differences in serious adverse events between deutetrabenazine and valbenazine.
• There is no population type or subgroup information available in the reviewed studies.